Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03666663 · ClinicalTrials.gov registry record · Phase 4
Sphenopalatine Ganglion Blocks RCT
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT03666663 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 10 participants.
The verdict
NCT03666663, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
RCT of Sphenopalatine Ganglion (SPG) Blocks using anesthetics vs. placebo for migraine.
Interventions
- DRUG Placebo
- DRUG Bupivacaine
- DRUG Lidocaine
- DRUG Ropivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03666663
The ClinicalTrials.gov registry entry for NCT03666663 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03666663 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03666663 about?
NCT03666663 is a clinical study titled "Sphenopalatine Ganglion Blocks RCT". RCT of Sphenopalatine Ganglion (SPG) Blocks using anesthetics vs. placebo for migraine.
What is the current status of trial NCT03666663?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2019-02-01. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT03666663?
The interventions under investigation include: Placebo (DRUG), Bupivacaine (DRUG), Lidocaine (DRUG), Ropivacaine (DRUG).
Who is sponsoring clinical trial NCT03666663?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.